Johnson, Radia M. http://orcid.org/0000-0002-9755-9307
Qu, Xueping http://orcid.org/0000-0002-4295-086X
Lin, Chu-Fang
Huw, Ling-Yuh
Venkatanarayan, Avinashnarayan
Sokol, Ethan
Ou, Fang-Shu http://orcid.org/0000-0003-1267-8735
Ihuegbu, Nnamdi
Zill, Oliver A. http://orcid.org/0000-0002-4329-2790
Kabbarah, Omar
Wang, Lisa
Bourgon, Richard http://orcid.org/0000-0002-5890-4374
de Sousa e Melo, Felipe http://orcid.org/0000-0002-9558-3098
Bolen, Chris
Daemen, Anneleen
Venook, Alan P.
Innocenti, Federico
Lenz, Heinz-Josef http://orcid.org/0000-0003-2178-9568
Bais, Carlos http://orcid.org/0000-0002-3668-4227
Funding for this research was provided by:
Genentech
Article History
Received: 19 August 2021
Accepted: 5 September 2022
First Online: 19 September 2022
Competing interests
: A.P.V. reports consulting/advisory role from Taiho Pharmaceutical, Bayer AG, Halozyme, Eisai; research funding from Genentech, Roche, Bristol Myers Squibb; royalties from Now-UpToDate for authoring and maintaining two authors and travel expenses from Genentech, Roche, Halozyme, Bayer AG. F.I. reports royalties from the Mayo Foundation on UGT1A1 testing. H.-J.L. is on the advisory Board/Consulting Genentech, Bristol Myers Squibb, Merck KG, Merck, Bayer, Oncocyte, Fulgent, G1 Therapeutics, Jazz Therapeutics, Biacara, Seattle Genetics, Abbvie, Amgen. E.S. Foundation Medicine, Roche; O. K. Zai Lab, San Francisco, CA; A. D. ORIC Pharmaceuticals; R. B., Freenome; A. V. Bristol Myers Squibb. Current affiliations of N.I.: Genentech, South San Francisco, CA; R.B.: Freenome, South San Francisco, CA; A.D.: ORIC Pharmaceuticals Inc., South San Francisco, CA; A.V.: Bristol Myers Squibb, Cambridge, MA; O. K., Zai Lab. and C.B.: Inhibrx, Inc, San Diego, CA. All other authors are employees and stockholders of Genentech/Roche.